BioNTech pays $205M for FDA fast-review voucher
Alpha Vantage · Quantisnow · · AI-summarised by FinFlash
BioNTech (BNTX) has agreed to acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The company plans to use this voucher to expedite the review of a future asset in its late-stage oncology pipeline, aiming to shorten FDA review times and potentially accelerate approval. The deal is contingent on customary closing conditions, including HSR antitrust clearance.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.